• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Hygienic Packaging Technology

    Trends in Solid Oral Dosage Delivery

    5 Reasons Paper Has No Place in Contract Manufacturing

    Injectable Drug Delivery Trends

    Pharmaceutical Manufacturing Equipment Trends
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Amgen to Acquire Five Prime Therapeutics for $1.9B

    Genesis Drug Discovery & Development Acquires Integrated Analytical Solutions

    CureVac, Novartis Ink COVID Vax Mfg. Pact

    Innoforce and dMed Enter Development Collaboration

    Matica Biotechnology Breaks Ground on Cell and Gene Therapy Site
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Reed-Lane Facility Virtual Tour

    CureVac, Novartis Ink COVID Vax Mfg. Pact

    Matica Biotechnology Breaks Ground on Cell and Gene Therapy Site

    WuXi AppTec Completes OXGENE Acquisition

    Trends in Solid Oral Dosage Delivery
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Reed-Lane Facility Virtual Tour

    Hygienic Packaging Technology

    Reshaping the Pharmaceutical Supply Chain

    Serialization: Level 5 Solution

    Covectra Introduces Next-Gen Serialization Solution
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Genesis Drug Discovery & Development Acquires Integrated Analytical Solutions

    Innoforce and dMed Enter Development Collaboration

    Matica Biotechnology Breaks Ground on Cell and Gene Therapy Site

    Four Female Leaders Appointed to Cell & Gene CDMO

    Strata Oncology Unveils Strata PATH Trial
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Guide to Maintaining Validation of Older Facilities: Why, When and How

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

    Top BioPharma Form Accumulus Synergy

    Global Biosciences Co. Selects ValGenesis VLMS

    Gene Therapy Co. Selects ValGenesis' SaaS Platform
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Syngene

    Aphena Pharma Solutions

    Cytovance Biologics

    Almac Group

    Adare Pharma Solutions
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Emergent BioSolutions

    Adare Pharma Solutions

    Cytovance Biologics

    Alcami

    Baxter BioPharma Solutions
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Features

    Expanding CMO/CDMO Roles

    Supporting smaller manufacturers with end-to-end services

    Expanding CMO/CDMO Roles
    Scott Cohon, Director, Sales and Trade Relations, Woodfield Pharmaceutical, LLC05.05.20
    Pharmaceutical manufacturers are feeling the heat. With cost containment a priority, especially in an era of COVID-19 and the threat of other previously unimagined business disruptions, the race to outsource development and manufacturing of life-saving drugs to trusted service providers is accelerating.

    The race for end-to-end outsourcing with contract manufacturing organizations (CMO) and contract development and manufacturing organizations (CDMO) takes on different meanings for smaller and virtual manufacturers compared with large conventional pharmaceutical companies. With fewer financial and human resources, smaller organizations rely on their outsourcing partners for additional services that many large manufacturers retain internally. Although smaller firms have equal dependence as large drug companies on their CMO/CDMO partners, their priority is focused on a different set of service offerings.

    Origins of Outsourcing
    Manufacturing is no longer a profit center for drug companies. When the economics of the situation became apparent during the mid-1990s, financial companies and venture capital (VC) firms swooped in. Their plan involved purchasing unprofitable business units from manufacturers and running them on their behalf. During these early years, the strategy did not unfold smoothly. The VC firms underestimated the reluctance of manufacturers to forfeit control over their manufacturing operations. More recently, skepticism was replaced with willingness as companies sold manufacturing and development operations that negatively affected the bottom line.

    Outsourcing Drivers
    The current drive from pharmaceutical manufacturers for outsourcing activities along a wider stretch of the supply chain is due to several factors. 

    First, there is a growing demand for generic medicines and biologics. The U.S. Food and Drug Administration (FDA) approved 1,171 generic drugs during their fiscal year 2019, a higher quantity compared with all previous years. During the same period, the FDA approved 48 new drugs and biologics. 

    Second, the development and manufacturing of medications is a capital-intensive business. With margins shrinking for generics, manufacturers are reducing the scale of their investments within this category.
    Third, complex manufacturing methods and equipment are required for new molecular structures and for the increasing sophistication of active pharmaceutical ingredient (API) materials.

    Manufacturers conserve resources by relying on outsourcing partners to expand their role leading to product commercialization. Consolidation of development and manufacturing activities with CMO/CDMO partners reduces cost, conserves resources, enables the manufacturer to focus on drug substance development and adds flexibility with access to equipment options beyond internal capabilities. 

    One-stop Shopping
    The CMO/CDMO market is competitive and resistant to consolidation with only a few large players with global reach. The ability to differentiate services is an important factor for increased business. Promoting multiple outsourced services as a one-stop-shop for manufacturers is a popular strategy.  

    Different CMO/CDMO companies pursue this profitable goal in one of two ways. The first pathway is a vertically integrated model built around API and excipient manufacturing. The second strategy is a virtually outsourced model that centers on performing quality and regulatory services with an acquired API source.

    Vertically-outsourced Model
    Pharmaceutical manufacturers that utilize a vertically outsourced model partner with CMO/CDMO firms that create their own API, excipients and components and often maintain project management responsibilities internally.

    This one-stop-shop model applies to larger organizations partnering with large manufacturer clients with branded products and international marketing reach. 

    Many of the clients retain personnel internally specializing in regulatory, quality assurance and commercialization. Due to their size, these clients have subject-matter experts on staff to actively communicate with the CMO/CDMO and manage the project from start to finish.

    Benefits of the vertically outsourced solution include consistency of product quality in all commercial markets globally because in many cases, one company is manufacturing the API for 100% of production. 

    Virtually-outsourced Model
    Unlike vertical outsourcing, middle to small-market clients utilizing the virtually outsourced solution work with their CMO/CDMO partners to source API and all components. Virtual manufacturers and smaller manufacturers with limited financial and human resources partner with these firms. 

    Many virtual manufacturers are substantial business entities so revenue alone is not a defining quality of companies seeking the virtual outsourced model. However, many companies pursuing this route are smaller with limited resources. Regardless of the size of their bottom line, these clients also tend to rely on their outsourcing partner for project management responsibilities that are internal functions within most larger manufacturers.

    Another distinguishing characteristic for clients of CMO/CDMO companies specializing in a virtual one-stop shop model is their preference for projects with regional or national scope. Vertically outsourced firms are better equipped for commercialization on a global scale.

    Manufacturers working with virtually outsourced CMO/CDMO partners do not have the resources or expertise to develop their own API. In this scenario, the CMO/CDMO partner manages procurement of API from trusted sources and creates alliances with companies providing complementary services including Third Party Logistics (3PL) capabilities and serialization support for DSCSA compliance.

    Although large CMO/CDMO companies may perform non-core activities for clients, these tasks are generally completed with more efficiency by a smaller scale CMO/CDMO that engages in these functions on a daily basis for multiple clients.

    End-to-end Relationships
    The differences between vertical and virtual outsourcing are quantitative in terms of services provided and also qualitative regarding the relationships between parties. 

    Many manufacturers partnering with vertically outsourced CMO/CDMO companies have operations in multiple countries and employ internal teams with deep expertise in compliance, quality assurance, development, manufacturing and materials management to oversee activities of their CMO/CDMO partner. These interactions tend to be knowledge-neutral in the sense that both the client and CMO/CDMO have similar levels of expertise.

    Relationships in the virtually outsourced model tend to be weighted toward the CMO/CDMO partner in cases where a small virtual manufacturer engages a contract manufacturer to manage the entire commercialization process. In some instances, the CMO/CDMO serves as a general consultant performing non-core functions including preparation of documents for the client to submit to authorities, customs and brokerage services and third party logistics solutions.

    Examples of Virtual Outsourcing
    A typical example of virtual outsourcing involves a small virtual manufacturer that partnered with a virtually outsourced CMO/CDMO to produce a generic version of a branded medication. 

    The CMO took ownership of the challenge and identified the regulatory stages required to support their submission to the FDA for approval. Documentation was created and prepared by the CMO on behalf of the client. These documents were submitted by the client for approval. A supply agreement was completed enabling purchase of API. Throughout the process, the project manager at the CMO communicated regularly with the client to review status and progress. When the API was acquired, the CMO arranged for importation and customs clearance to the manufacturing facility. 

    With the API in hand, the CMO conducted analytical testing based on previously created scientific methods, followed by validation of all methods and materials.

    For the manufacturing process to begin, all related components and excipients were researched, acquired and tested for suitability. A coordinated effort was organized to comply with DSCSA regulations for product serialization. This client also relied on their CMO to design the product label. As a final step, the client utilized a trusted partner of the CMO for third party logistics services.

    In a second typical case, a smaller virtual manufacturer with comprehensive knowledge of pharmaceutical science that possessed less knowledge about commercialization approached a virtually-outsourced CMO/CDMO for assistance bringing their product to market. Their medication was approved in Canada and they were seeking FDA approval. The CMO/CDMO undertook the research and development required to submit proper documentation. This project included complete formulation development, analytical testing, method and material validation. Results and documentation were generated and prepared for submission by the client. In this case, the CMO/CDMO also referred the client to potential partners with sales and marketing expertise in anticipation of entry into the U.S. market. 

    Virtually outsourced CMO/CDMO companies attempt to broaden their knowledge base as much as possible because the skillset of their client base varies considerably. The virtually outsourced CMO/CDMO must be prepared for research and development projects as well as procurement of critical components—bottles, pumps, sprayers, droppers—to meet project requirements for safety, efficacy and cost. And sometimes project requirements change unexpectedly as when a client requests a custom-designed label that was not envisioned before contract signing.

    Conclusion
    The goal of innovative CMO/CDMO partners to offer ‘end-to-end’ solutions takes on different meanings depending on the desired client base. Larger-scale CMO/CDMO companies begin their end-to-end services with development and manufacture of the API and progress through each service with regular oversight by the client company. This vertically-outsourced business model focuses on large manufacturers with a global presence. These manufacturers maintain internal departments with specific knowledge of regulatory compliance, quality assurance, pharmaceutical development, sales and marketing that work alongside their CMO/CDMO partners.

    Contrast the vertically-outsourced model with the virtually-outsourced model for providing end-to-end services. CMO/CDMO companies offering virtually-outsourced solutions cater to virtual or smaller manufacturers with limited geographic reach. These CMO/CDMO partners acquire API from trusted sources and tend to oversee project management on behalf of their clients. Relationships in the virtually-outsourced model focus on guiding the client through the development and commercialization process. In many cases these clients do not have the resources to maintain subject-matter experts and therefore rely heavily on their CMO/CDMO partner for recommendations and insights to reach the finish line.

    Future Prospects
    Vertical and virtual end-to-end outsourcing models are poised for further growth. As the coronavirus pandemic compels new strategies to better prepare for future disruption, the pharmaceutical outsourcing industry will benefit from increased reliance on domestic development and production of medications to enhance security and guarantee supply. 


    Scott Cohon is the Director of Sales and Trade Relations at Woodfield Pharmaceutical, LLC.  He is responsible for expanding relationships with current clients and trading partners. In his role Scott evaluates changing needs of manufacturers and implements services that support commercialization strategies.

    Related Features

    • Solid Dosage/Semi-solids
      Hygienic Packaging Technology

      Hygienic Packaging Technology

      Growing consumer demand for health products highlights hygienic packaging.
      John Brown, Vice President of Global Marketing, Selig 03.01.21

    • Drug Delivery | Solid Dosage/Creams/Ointments
      Trends in Solid Oral Dosage Delivery

      Trends in Solid Oral Dosage Delivery

      Capsule demand continues to rise due to this delivery system’s versatility.
      Anita Solanki, Milind Biyani and Jnanadeva Bhat, PhD , ACG Capsules 03.01.21

    • Information Technology
      5 Reasons Paper Has No Place in Contract Manufacturing

      5 Reasons Paper Has No Place in Contract Manufacturing

      Digital solutions create more efficient manufacturing processes and eliminate delays.
      Dave Edwards, Chief Revenue Officer, MasterControl 03.01.21


    • Drug Delivery | Parenterals
      Injectable Drug Delivery Trends

      Injectable Drug Delivery Trends

      How medication trends are driving the shift to patient-friendly drug delivery systems.
      Peter Soelkner, Managing Director, Vetter 03.01.21

    • Pharmaceutical Manufacturing  Equipment Trends

      Pharmaceutical Manufacturing Equipment Trends

      Demand for flexibility remains the driving force behind equipment systems.
      Kristin Brooks, Managing Editor, Contract Pharma 03.01.21

    • Drug Delivery | Solid Dosage/Creams/Ointments
      Oral Solids:   Market & Technology Trends

      Oral Solids: Market & Technology Trends

      Oral solids remain the preferred route of drug delivery due to their cost-effectiveness, ease of manufacturing, and patient-friendly dose form options.
      Tim Wright, Editor, Contract Pharma 03.01.21


    • Nutraceutical Manufacturing:  Meeting the Challenges of Today, Planning for  Tomorrow

      Nutraceutical Manufacturing: Meeting the Challenges of Today, Planning for Tomorrow

      Companies continue balancing high demand, supply disruption, and worker safety during the pandemic.
      Sean Moloughney, Editor, Nutraceuticals World 03.01.21

    • 2021 Contract  Manufacturing Survey

      2021 Contract Manufacturing Survey

      Our fourth annual audience poll indicates continued reliance on manufacturing partners, particularly for small businesses.
      Sean Moloughney, Editor, Nutraceuticals World 03.01.21

    • APIs
      Small Molecule Development Trends

      Small Molecule Development Trends

      A Q&A with Cambrex Edinburgh’s site director, Mark Benger.
      Tim Wright, Editor, Contract Pharma 03.01.21


    • APIs | Cytotoxics and High Potency Manufacturing
      Challenges & Opportunities Facing Small & Emerging Biopharma Companies

      Challenges & Opportunities Facing Small & Emerging Biopharma Companies

      A Q&A with Christian Dowdeswell, vice president and head of commercial development for small molecules at Lonza.
      Tim Wright, Editor, Contract Pharma 03.01.21

    • Drug Delivery | Solid Dosage/Creams/Ointments
      Medicated Chewing Gum: A Modern Oral Drug Delivery System

      Medicated Chewing Gum: A Modern Oral Drug Delivery System

      Development and manufacture of medicated chewing gum continues to gain momentum.
      Rukayat Adedeji, Contributing Writer 03.01.21

    • APIs
      Small Molecule API CDMO: A Capital Intensive Business?

      Small Molecule API CDMO: A Capital Intensive Business?

      Exploring small molecule API market trends.
      Dr. Michele Jermini and Dr. Enrico Polastro, Contributing Writers 03.01.21


    • Serialization
      Serialization: Level 5 Solution

      Serialization: Level 5 Solution

      Why a Level 5 solution is required for small pharma companies to fully harness serialization investment.
      Steve Wood, President & CEO, Covectra 03.01.21

    • Solid Dosage/Creams/Ointments
      High Drug Loading Amorphous Solid Dispersions

      High Drug Loading Amorphous Solid Dispersions

      A Novel Tablet Architecture for Amorphous Solid Dispersions to Achieve High Drug Loadings
      Deanna Mudie and Aaron Stewart, Lonza 01.27.21

    • Parenterals
      Parenteral Drug Delivery Trends

      Parenteral Drug Delivery Trends

      A Q&A with Lubrizol Life Science Health’s CDMO Division President, Rob Lee.
      Kristin Brooks, Managing Editor, Contract Pharma 01.27.21

    Trending
    • Catalent Acquires Delphi Genetics
    • BMS Expands Cell Therapy Manufacturing Capabilities
    • AbbVie Opts To Acquire Mitokinin
    • Four Female Leaders Appointed To Cell & Gene CDMO
    • WuXi AppTec Completes OXGENE Acquisition
    Breaking News
    • Amgen to Acquire Five Prime Therapeutics for $1.9B
    • Genesis Drug Discovery & Development Acquires Integrated Analytical Solutions
    • CureVac, Novartis Ink COVID Vax Mfg. Pact
    • Innoforce and dMed Enter Development Collaboration
    • Matica Biotechnology Breaks Ground on Cell and Gene Therapy Site
    View Breaking News >
    CURRENT ISSUE

    March 2021

    • Hygienic Packaging Technology
    • Trends in Solid Oral Dosage Delivery
    • 5 Reasons Paper Has No Place in Contract Manufacturing
    • Injectable Drug Delivery Trends
    • Pharmaceutical Manufacturing Equipment Trends
    • Oral Solids: Market & Technology Trends
    • Nutraceutical Manufacturing: Meeting the Challenges of Today, Planning for Tomorrow
    • 2021 Contract Manufacturing Survey
    • Small Molecule Development Trends
    • Challenges & Opportunities Facing Small & Emerging Biopharma Companies
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    IFT Transitions 2021 Annual Event to Digital Experience
    NY Federal Judge Enters Permanent Injunction Against Dietary Supplement Manufacturer
    Statins May Contribute to Vascular Calcification by Inhibiting Vitamin K-Dependent Proteins
    Coatings World

    Latest Breaking News From Coatings World

    Chromaflo Technologies Adds Benjamin Woeste as Territory Sales Manager
    Maroon Group Acquires Cary Company's Raw Materials, Specialty Chemicals Distribution Business
    Matt Fogel Named Mule-Hide's Territory Manager – Southern Virginia
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    EchoNous Expands Its Kosmos Hardware Platform
    Medtronic Begins Trial to Assess Novel Ablation Tech to Treat AFib
    Europe's Cross-Border Medtech Deal Activity Rises in Q4 2020
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Amgen to Acquire Five Prime Therapeutics for $1.9B
    Genesis Drug Discovery & Development Acquires Integrated Analytical Solutions
    CureVac, Novartis Ink COVID Vax Mfg. Pact
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Estée Lauder Establishes Equity and Engagement Center of Excellence
    L'Oreal On How It Will Shape Beauty's Future at Today's Transparency Summit
    C.O. Bigelow Earns Praise as NYC's Oldest Family-Run Apothecary
    Happi

    Latest Breaking News From Happi

    Avon Launches Vegan Skin Care Line
    Inolex Appoints VP Marketing
    Decorté Launches AI Diagnostics in US
    Ink World

    Latest Breaking News From Ink World

    Massilly North America Adds Koenig & Bauer MetalStar 3 Metal Decorating Press
    Hydrocarbon Solvents Market to Surpass $8.1 Billion by 2030
    Access Direct Mail Doubles Revenue with SCREEN's Truepress Jet520HD
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Henkel publishes 30th Sustainability Report
    Avery Dennison Smartrac launches new Circus Pro inlays
    Springfield Solutions highlights digital label embellishments
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    FPInnovations Develops Biodegradable Mask
    Sani Professional Sanitizing and Disinfecting Products Approved by EPA
    Autefa Solutions Offers Fully Automated Line for Protective Mask Production
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Bioventus Appoints Managing Director, China and Asia Pacific
    Full-Year Sales Down 12 Percent at Zimmer Biomet
    Lincotek Medical Expands Coatings and Additive Capacity
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Comercial Kywi Improves Customer Service, Front-Store Operations with Zebra Mobile Solution
    Global Printed Circuit Board Market Projected to Reach $69.32 Billion by 2027
    Global Smart Glass Market to Register 6.8% CAGR Between 2021-28: Grand View Research

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login